GTC
SYRE icon

Ghost Tree Capital’s Spyre Therapeutics SYRE Stock Holding History

Ghost Tree Capital’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.76M Sell
60,000
-190,237
-76% -$5.3M 0.53% 48
2024
Q2 		$5.88M Buy
250,237
+150,237
+150% +$5.07M 1.84% 23
2024
Q1 		$3.79M Buy
+100,000
New +$2.9M 1.05% 32
2023
Q1 		– Sell
-32,000
Closed -$360K – 63
2022
Q4 		$360K Sell
32,000
-8,000
-20% -$144K 0.15% 35
2022
Q3 		$526K Buy
40,000
+3,000
+8% +$37.1K 0.15% 44
2022
Q2 		$467K Buy
37,000
+9,536
+35% +$334K 0.24% 31
2022
Q1 		$1.58M Buy
+27,464
New +$2.31M 0.34% 39
2016
Q4 		– Sell
-2,000
Closed -$321K – 93
2016
Q3 		$321K Hold
2,000
– – 0.05% 86
2016
Q2 		$243K Buy
+2,000
New +$383K 0.07% 61

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ghost Tree Capital's SYRE Position: Q3 2024 in Review

Ghost Tree Capital reduced its Spyre Therapeutics (SYRE) stake by 76% in Q3 2024, selling an estimated $5.3M and leaving 60,000 shares worth $1.76M. The position accounts for 0.53% of the portfolio, ranked #48.

Ghost Tree Capital first reported a position in SYRE in Q2 2016 and has held it in 9 quarters since. The position peaked at $5.88M in Q2 2024. 119 funds tracked by Wall St. Rank hold SYRE as of Q3 2024.

  • Ghost Tree Capital held 60,000 shares of Spyre Therapeutics worth $1.76M as of Q3 2024.
  • Ghost Tree Capital sold 190,237 Spyre Therapeutics shares in Q3 2024, an estimated $5.3M.
  • Spyre Therapeutics made up 0.53% of Ghost Tree Capital's portfolio in Q3 2024, its #48 holding.
  • Ghost Tree Capital first reported a position in Spyre Therapeutics in Q2 2016 and has held it in 9 quarters since.
  • Ghost Tree Capital's Spyre Therapeutics position peaked at $5.88M in Q2 2024.
  • 119 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.